Meropenem Aurovit

Meropenem, the active ingredient in Meropenem Aurovit, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It treats a range of serious bacterial infections in hospitalized patients, including pneumonia, intra‑abdominal infections, meningitis, and sepsis.

GNH USA supplies Meropenem Aurovit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem Aurovit is a broad‑spectrum carbapenem used to treat severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure. - Complicated skin and soft tissue infections: eliminates resistant Gram‑negative and Gram‑positive pathogens. - Community‑acquired pneumonia: achieves rapid bacterial clearance. - Hospital‑acquired pneumonia: targets multidrug‑resistant organisms. - Meningitis: penetrates the cerebrospinal fluid to treat central nervous system infections. - Sepsis: offers systemic antibacterial activity in critically ill patients.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Rash: erythematous skin eruption. - Headache: transient and usually resolves. - Elevated liver enzymes: transient increase in ALT/AST. - Injection site phlebitis: local irritation at the infusion site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Anaphylaxis: acute hypersensitivity reaction requiring emergency care. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity reactions: including serum sickness‑like manifestations.

Use meropenem with caution, adhering to clinical guidelines and patient monitoring.

- Renal function assessment: adjust dose in patients with impaired clearance. - Hypersensitivity screening: avoid in individuals with known carbapenem allergy. - Pregnancy considerations: safety not established; weigh benefits against potential risks. - Seizure risk monitoring: observe patients with CNS disorders or high doses. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with other medications, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Valproic acid: meropenem reduces serum concentrations, risking seizure breakthrough. - Warfarin: may enhance anticoagulant effect, increasing INR. - Aminoglycosides: combined use can heighten nephrotoxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may affect electrolyte balance during therapy. - NSAIDs: concurrent use can increase risk of renal impairment. - Other antibiotics: potential antagonism when combined with bacteriostatic agents.